300 related articles for article (PubMed ID: 30277644)
1. Drug Design Concepts for LSD1-Selective Inhibitors.
Ota Y; Suzuki T
Chem Rec; 2018 Dec; 18(12):1782-1791. PubMed ID: 30277644
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and evaluation of γ-turn mimetics as LSD1-selective inhibitors.
Ota Y; Miyamura S; Araki M; Itoh Y; Yasuda S; Masuda M; Taniguchi T; Sowa Y; Sakai T; Itami K; Yamaguchi J; Suzuki T
Bioorg Med Chem; 2018 Feb; 26(3):775-785. PubMed ID: 29331452
[TBL] [Abstract][Full Text] [Related]
3. Identifying the novel inhibitors of lysine-specific demethylase 1 (LSD1) combining pharmacophore-based and structure-based virtual screening.
Sun XD; Zheng YC; Ma CY; Yang J; Gao QB; Yan Y; Wang ZZ; Li W; Zhao W; Liu HM; Ding L
J Biomol Struct Dyn; 2019 Oct; 37(16):4200-4214. PubMed ID: 30366512
[TBL] [Abstract][Full Text] [Related]
4. Structural insight into inhibitors of flavin adenine dinucleotide-dependent lysine demethylases.
Niwa H; Umehara T
Epigenetics; 2017 May; 12(5):340-352. PubMed ID: 28277979
[TBL] [Abstract][Full Text] [Related]
5. Raloxifene, identified as a novel LSD1 inhibitor, suppresses the migration of renal cell carcinoma.
Ma Y; Zheng Y; Ji Y; Wang X; Ye B
Future Med Chem; 2021 Mar; 13(6):533-542. PubMed ID: 33527838
[No Abstract] [Full Text] [Related]
6. Design, synthesis and biological activity of 3-oxoamino-benzenesulfonamides as selective and reversible LSD1 inhibitors.
Xi J; Xu S; Wu L; Ma T; Liu R; Liu YC; Deng D; Gu Y; Zhou J; Lan F; Zha X
Bioorg Chem; 2017 Jun; 72():182-189. PubMed ID: 28460360
[TBL] [Abstract][Full Text] [Related]
7. Discovery of resveratrol derivatives as novel LSD1 inhibitors: Design, synthesis and their biological evaluation.
Duan YC; Guan YY; Zhai XY; Ding LN; Qin WP; Shen DD; Liu XQ; Sun XD; Zheng YC; Liu HM
Eur J Med Chem; 2017 Jan; 126():246-258. PubMed ID: 27888721
[TBL] [Abstract][Full Text] [Related]
8. LSD1 Histone Demethylase Assays and Inhibition.
Hayward D; Cole PA
Methods Enzymol; 2016; 573():261-78. PubMed ID: 27372757
[TBL] [Abstract][Full Text] [Related]
9. Tranylcypromine Based Lysine-Specific Demethylase 1 Inhibitor: Summary and Perspective.
Dai XJ; Liu Y; Xiong XP; Xue LP; Zheng YC; Liu HM
J Med Chem; 2020 Dec; 63(23):14197-14215. PubMed ID: 32931269
[TBL] [Abstract][Full Text] [Related]
10. Reversible Lysine Specific Demethylase 1 (LSD1) Inhibitors: A Promising Wrench to Impair LSD1.
Dai XJ; Liu Y; Xue LP; Xiong XP; Zhou Y; Zheng YC; Liu HM
J Med Chem; 2021 Mar; 64(5):2466-2488. PubMed ID: 33619958
[TBL] [Abstract][Full Text] [Related]
11. Development and Structural Evaluation of N-Alkylated trans-2-Phenylcyclopropylamine-Based LSD1 Inhibitors.
Niwa H; Sato S; Handa N; Sengoku T; Umehara T; Yokoyama S
ChemMedChem; 2020 May; 15(9):787-793. PubMed ID: 32166890
[TBL] [Abstract][Full Text] [Related]
12. Identification of Novel Selective Lysine-Specific Demethylase 1 (LSD1) Inhibitors Using a Pharmacophore-Based Virtual Screening Combined with Docking.
Zhou C; Kang D; Xu Y; Zhang L; Zha X
Chem Biol Drug Des; 2015 Jun; 85(6):659-71. PubMed ID: 25346381
[TBL] [Abstract][Full Text] [Related]
13. Structure-activity studies on N-Substituted tranylcypromine derivatives lead to selective inhibitors of lysine specific demethylase 1 (LSD1) and potent inducers of leukemic cell differentiation.
Schulz-Fincke J; Hau M; Barth J; Robaa D; Willmann D; Kürner A; Haas J; Greve G; Haydn T; Fulda S; Lübbert M; Lüdeke S; Berg T; Sippl W; Schüle R; Jung M
Eur J Med Chem; 2018 Jan; 144():52-67. PubMed ID: 29247860
[TBL] [Abstract][Full Text] [Related]
14. Design, Synthesis, and In Vitro Evaluation of Novel Histone H3 Peptide-Based LSD1 Inactivators Incorporating α,α-Disubstituted Amino Acids with γ-Turn-Inducing Structures.
Ota Y; Kakizawa T; Itoh Y; Suzuki T
Molecules; 2018 May; 23(5):. PubMed ID: 29734782
[TBL] [Abstract][Full Text] [Related]
15. Histone H3 peptide based LSD1-selective inhibitors.
Kakizawa T; Ota Y; Itoh Y; Tsumoto H; Suzuki T
Bioorg Med Chem Lett; 2015 May; 25(9):1925-8. PubMed ID: 25827526
[TBL] [Abstract][Full Text] [Related]
16. Structure-based design and discovery of potent and selective lysine-specific demethylase 1 (LSD1) inhibitors.
Nie Z; Shi L; Lai C; Severin C; Xu J; Del Rosario JR; Stansfield RK; Cho RW; Kanouni T; Veal JM; Stafford JA; Chen YK
Bioorg Med Chem Lett; 2019 Jan; 29(1):103-106. PubMed ID: 30409536
[TBL] [Abstract][Full Text] [Related]
17. Tying up tranylcypromine: Novel selective histone lysine specific demethylase 1 (LSD1) inhibitors.
Ji YY; Lin SD; Wang YJ; Su MB; Zhang W; Gunosewoyo H; Yang F; Li J; Tang J; Zhou YB; Yu LF
Eur J Med Chem; 2017 Dec; 141():101-112. PubMed ID: 29031059
[TBL] [Abstract][Full Text] [Related]
18. Mining the Dynamical Properties of Substrate and FAD Binding Pockets of LSD1: Hints for New Inhibitor Design Direction.
Yang K; Liu H
J Chem Inf Model; 2024 Jun; 64(12):4773-4780. PubMed ID: 38837697
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological activity of 4-(4-benzyloxy)phenoxypiperidines as selective and reversible LSD1 inhibitors.
Xi J; Xu S; Zhang L; Bi X; Ren Y; Liu YC; Gu Y; Xu Y; Lan F; Zha X
Bioorg Chem; 2018 Aug; 78():7-16. PubMed ID: 29524666
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and biological evaluation of novel dual inhibitors targeting lysine specific demethylase 1 (LSD1) and histone deacetylases (HDAC) for treatment of gastric cancer.
Duan YC; Jin LF; Ren HM; Zhang SJ; Liu YJ; Xu YT; He ZH; Song Y; Yuan H; Chen SH; Guan YY
Eur J Med Chem; 2021 Aug; 220():113453. PubMed ID: 33957387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
